ES2183952T3 - Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico. - Google Patents

Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico.

Info

Publication number
ES2183952T3
ES2183952T3 ES96915595T ES96915595T ES2183952T3 ES 2183952 T3 ES2183952 T3 ES 2183952T3 ES 96915595 T ES96915595 T ES 96915595T ES 96915595 T ES96915595 T ES 96915595T ES 2183952 T3 ES2183952 T3 ES 2183952T3
Authority
ES
Spain
Prior art keywords
tripycholinate
diabetes
type
chrome
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96915595T
Other languages
English (en)
Inventor
Mark F Mccarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
Nutrition 21 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 LLC filed Critical Nutrition 21 LLC
Application granted granted Critical
Publication of ES2183952T3 publication Critical patent/ES2183952T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

Abstract

SE DESCRIBE UN METODO PARA ESTABILIZAR LOS NIVELES DE GLUCOSA EN SANGRE Y REDUCIR LA HIPERGLICEMIA ASOCIADA CON LA DIABETES DE TIPO II. SE ADMINISTRA EL TRIPICOLINATO CROMICO SINTETICO BIEN VIA ORAL O PARENTERAL A UN SER HUMANO QUE LO NECESITE A UNA DOSIS ENTRE APROXIMADAMENTE 1.000 Y 10.000 MICROGRAMOS POR DIA.
ES96915595T 1995-05-12 1996-05-08 Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico. Expired - Lifetime ES2183952T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/440,362 US6329361B1 (en) 1995-05-12 1995-05-12 High-dose chromic picolinate treatment of type II diabetes

Publications (1)

Publication Number Publication Date
ES2183952T3 true ES2183952T3 (es) 2003-04-01

Family

ID=23748461

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96915595T Expired - Lifetime ES2183952T3 (es) 1995-05-12 1996-05-08 Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico.

Country Status (15)

Country Link
US (1) US6329361B1 (es)
EP (1) EP0825861B1 (es)
JP (1) JP3699124B2 (es)
AR (1) AR004486A1 (es)
AT (1) ATE227127T1 (es)
AU (1) AU5733796A (es)
BR (1) BR9608835A (es)
DE (1) DE69624699T2 (es)
DK (1) DK0825861T3 (es)
ES (1) ES2183952T3 (es)
IL (1) IL118222A (es)
PT (1) PT825861E (es)
RU (1) RU2195934C2 (es)
WO (1) WO1996035421A1 (es)
ZA (1) ZA963735B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
EP1001793B1 (en) * 1997-08-08 2005-09-14 Nutrition 21 Chromium/biotin treatment of type ii diabetes
EP0925790A1 (en) * 1997-12-17 1999-06-30 Kartar Dr. Lalvani Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM)
US5932258A (en) * 1998-04-06 1999-08-03 The Iams Company Composition and process for improving glucose metabolism in companion animals
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US6143301A (en) * 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5905075A (en) * 1998-08-28 1999-05-18 Ambi Inc. Chromium nicotinate compositions and uses thereof
US6376549B1 (en) 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US6852760B1 (en) 1998-09-17 2005-02-08 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment for glucose metabolism disorders
CN1665566A (zh) 2000-09-21 2005-09-07 营养21公司 用铬络合物、共轭脂肪酸和 /或共轭脂肪醇治疗糖尿病、减少身体脂肪、改善胰岛素敏感性、缓解高血糖症和高胆固醇血症的方法和组合物
EP1496881A4 (en) * 2002-04-23 2007-04-04 Nutrition 21 Inc CHROMIUM COMPOSITIONS AND METHOD FOR USE THEREOF FOR INHIBITING MEDICAMENT-RELATED INSULIN RESISTANCE
EP1504762B1 (en) * 2002-05-14 2010-08-04 Nipro Corporation Medicine for prevention of and treatment for familial amyloid polyneuropathy
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
US20050019435A1 (en) * 2003-07-21 2005-01-27 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
AU2008210586B2 (en) * 2007-01-31 2013-07-04 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
PL3050568T3 (pl) 2007-03-13 2021-06-14 Jds Therapeutics, Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) * 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2448412B1 (en) 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
EP3256004A1 (en) 2015-02-13 2017-12-20 Mars, Incorporated Pet food feeding system
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5164384A (en) 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula

Also Published As

Publication number Publication date
AR004486A1 (es) 1998-12-16
JPH11504941A (ja) 1999-05-11
EP0825861B1 (en) 2002-11-06
RU2195934C2 (ru) 2003-01-10
DE69624699D1 (de) 2002-12-12
EP0825861A1 (en) 1998-03-04
MX9708628A (es) 1998-06-28
AU5733796A (en) 1996-11-29
BR9608835A (pt) 1999-12-07
ZA963735B (en) 1997-01-09
US6329361B1 (en) 2001-12-11
DE69624699T2 (de) 2003-03-20
IL118222A0 (en) 1996-09-12
IL118222A (en) 2000-06-01
JP3699124B2 (ja) 2005-09-28
WO1996035421A1 (en) 1996-11-14
PT825861E (pt) 2003-03-31
DK0825861T3 (da) 2003-03-03
ATE227127T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
ES2183952T3 (es) Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico.
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
MY155270A (en) Use of glp-1 or analogs in treatment of stroke
ES2000428T3 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
YU10699A (sh) Upotreba glp-1, glp-1 analoga i glp-1 derivata za proizvodnju leka
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
TNSN00206A1 (en) Method for treating diabetes
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
SE9201573D0 (sv) Use of igf-1
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
ES8801580A1 (es) Un procedimiento para producir una solucion de glicosido de antraciclina exenta de pirogenos, esteril
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
DE69941629D1 (de) Durchsichtige transdermale nicotinabgabevorrichtungen
GR871846B (en) Injectable ready to use solutions containing an antitumor anthracycline glycoside
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
ES2108642B1 (es) Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
SE9101341D0 (sv) New medicinal use
RU94023697A (ru) Средство для лечения инфекционного токсикоза у детей раннего возраста
ITMI922040A1 (it) Composizioni farmaceutiche per il trattamento di stati di iperaggregabilita' piastrinica
MX9705920A (es) Tratamiento de neuropatia diabetica.
UA29943A (uk) Спосіб лікування хворих на хронічний гепатит